tbuckley/cabot-search huggingface dataset:
Pelvis Plus Prostate Radiation Therapy and the Risk of Death in Men With Newly Diagnosed Node-Positive Prostate Cancer
Authors: Anthony V. D’Amico
Journal: JAMA Oncology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Factors that predict a poor outcome 5–8 years after the diagnosis of patellofemoral pain: a multicentre observational analysis
Authors: N E Lankhorst, M van Middelkoop, K M Crossley, S M A Bierma-Zeinstra, E H G Oei, B Vicenzino, N J Collins
Journal: British Journal of Sports Medicine (2015)

Patellofemoral pain (PFP) has traditionally been viewed as self-limiting, but recent studies show that a large proportion of patients report chronic knee pain at long-term follow-up. We identified those patients with an unfavourable recovery ('moderate improvement' to 'worse than ever' measured on a Likert scale) and examined whether there is an association between PFP and osteoarthritis (OA) at 5-8-year follow-up.Long-term follow-up data were derived from 2 randomised controlled trials (n=179, n=131). Patient-reported measures were obtained at baseline. Pain severity (100 mm visual analogue scale (VAS)), function (Anterior Knee Pain Scale (AKPS)) and self-reported recovery were measured 5-8 years later, along with knee radiographs. Multivariate backward stepwise linear regression analyses were used to evaluate the prognostic ability of baseline pain duration, pain VAS and AKPS on outcomes of pain VAS and AKPS at 5-8 years.60 (19.3%) participants completed the questionnaires at 5-8-year follow-up (45 women, mean age at baseline 26 years) and 50 underwent knee radiographs. No differences were observed between responders and non-responders regarding baseline demographics, and 3-month and 12-month pain severity and recovery. 34 (57%) reported unfavourable recovery at 5-8 years. 48 out of 50 participants (98%) had no signs of radiographic knee OA. Multivariate models revealed that baseline PFP duration (>12 months; R(2)=0.22) and lower AKPS (R(2)=0.196) were significant predictors of poor prognosis at 5-8 years on measures of worst pain VAS and AKPS, respectively.More than half of participants with PFP reported an unfavourable recovery 5-8 years after recruitment, but did not have radiographic knee OA. Longer PFP duration and worse AKPS score at baseline predict poor PFP prognosis. Education of health practitioners and the general public will provide patients with more realistic expectations regarding prognosis.
Tolerance to Extensively Heated (Baked) Milk-Clinical and Immunologic Phenotype
Authors: Hugh A. Sampson, George N. Konstantinou, Jacob Daniel Kattan, Madhan Masilamani, Beth D. Strong, Elizabeth Paynter, Tee Bahnson, Anna H. Nowak-Wegrzyn
Journal: Journal of Allergy and Clinical Immunology (2013)
Creatine kinase BB and beta-2-microglobulin as markers of CNS metastases in patients with small-cell lung cancer.
Authors: A G Pedersen, F W Bach, M Nissen, F Bach
Journal: Journal of Clinical Oncology (1985)

Creatine kinase (CK) and its BB isoenzyme (CK-BB) were measured in CSF in 65 evaluable patients suspected of CNS metastases secondary to small-cell lung cancer (SCLC). In addition, CSF and plasma levels of beta-2-microglobulin (beta-2-m) were measured in a group of 73 evaluable patients. Of the 65 patients analysed for CK-BB, 17 had meningeal carcinomatosis (MC), 26 had parenchymal metastases only, and 22 had no CNS disease. Patients with MC had a significantly higher CK-BB concentration in CSF than did patients belonging to the other two groups (P less than .01). Taking 0.4 U/L (upper limit in patients without CNS disease) as a cut-off point, 15 patients (88%) with MC had elevated CSF concentrations of CK-BB. Patients without CNS metastases had no CSF levels exceeding this value, whereas five patients with multiple CNS metastases did. Receiver operating characteristic (ROC) analysis suggests that CK-BB may be useful in distinguishing MC among patients suspected of having CNS metastases, and CK-BB appears superior to total CK, CSF protein, and CSF lactic dehydrogenase (LDH). In 12 patients with MC at autopsy, CK-BB was, with the above cut-off point, elevated in six patients with a false negative cytology. Of the 73 patients examined for beta-2-m, 18 had MC, 30 had parenchymatous metastases only, and 25 patients had no CNS metastases. The CSF concentrations in the three groups were not significantly different. The median concentrations in the groups were 133 nmol/L, 125 nmol/L, and 107 nmol/L, respectively. The ratios between beta-2-m in CSF and plasma were also not significantly different between the three groups. Thus, the data on CK-BB are promising, and further studies are warranted to see if the usefulness of CK-BB can be more firmly established. By contrast, beta-2-m has no role as a marker of CNS disease secondary to SCLC.
Impact Of Female Donor On Allogeneic Stem Cell Transplantation Outcome Of Male Recipient After T-Cell Depletion By Rabbit Antithymocyte Globulin
Authors: Claire Calmettes, Stephane Vigouroux, Reza Tabrizi, Arnaud Pigneux, Thibaut Leguay, Krimo Bouabdallah, Marie-Sarah Dilhuydy, Cedric Duclos, Axelle Lascaux, Pierre-Yves Dumas, Sophie Dimicoli-Salazar, Gerald Marit, Noel Milpied
Journal: Blood (2013)
The SCID Mouse Mutant: Definition, Characterization, and Potential Uses
Authors: M J Bosma, A M Carroll
Journal: Annual Review of Immunology (1991)

Mice homozygous for the scid mutation (scid mice) are severely deficient in functional B and T lymphocytes. The mutation appears to impair the recombination of antigen receptor genes and thereby causes an arrest in the early development of B and T lineage-committed cells; other hematopoietic cell types appear to develop and function normally. The arrest in lymphocyte development is not absolute; some young adult scid mice are "leaky" and generate a few clones of functional B and T cells. By 10-14 months of age, virtually all scid mice are leaky. Scid mice readily support normal lymphocyte differentiation and can be reconstituted with normal lymphocytes from other mice and even partially reconstituted with human lymphocytes. They also support the growth of allogeneic and xenogeneic tumors. Thus, scid mice are of interest for studies of both normal and abnormal lymphocyte development and function. In addition, they can be used to study the function of nonlymphoid cell types in the absence of lymphocytes.
High-Throughput Identification of<i>Cis</i>-Regulatory Rewiring Events in Yeast
Authors: Shrutii Sarda, Sridhar Hannenhalli
Journal: Molecular Biology and Evolution (2015)

A coregulated module of genes (“regulon”) can have evolutionarily conserved expression patterns and yet have diverged upstream regulators across species. For instance, the ribosomal genes regulon is regulated by the transcription factor (TF) TBF1 in Candida albicans, while in Saccharomyces cerevisiae it is regulated by RAP1. Only a handful of such rewiring events have been established, and the prevalence or conditions conducive to such events are not well known. Here, we develop a novel probabilistic scoring method to comprehensively screen for regulatory rewiring within regulons across 23 yeast species. Investigation of 1,713 regulons and 176 TFs yielded 5,353 significant rewiring events at 5% false discovery rate (FDR). Besides successfully recapitulating known rewiring events, our analyses also suggest TF candidates for certain processes reported to be under distinct regulatory controls in S. cerevisiae and C. albicans, for which the implied regulators are not known: 1) Oxidative stress response (Sc-MSN2 to Ca-FKH2) and 2) nutrient modulation (Sc-RTG1 to Ca-GCN4/Ca-UME6). Furthermore, a stringent screen to detect TF rewiring at individual genes identified 1,446 events at 10% FDR. Overall, these events are supported by strong coexpression between the predicted regulator and its target gene(s) in a species-specific fashion (>50-fold). Independent functional analyses of rewiring TF pairs revealed greater functional interactions and shared biological processes between them (P = 1 × 10−3). Our study represents the first comprehensive assessment of regulatory rewiring; with a novel approach that has generated a unique high-confidence resource of several specific events, suggesting that evolutionary rewiring is relatively frequent and may be a significant mechanism of regulatory innovation.
Human epicardial cell-conditioned medium contains HGF/IgG complexes that phosphorylate RYK and protect against vascular injury
Authors: Krithika S. Rao, Alexander Aronshtam, Keara L. McElory-Yaggy, Benjamin Bakondi, Peter VanBuren, Burton E. Sobel, Jeffrey L. Spees
Journal: Cardiovascular Research (2015)

AimsThe aim of this study was to evaluate the paracrine activity of human epicardial-derived cells (hEPDCs) to screen for secreted vasoprotective factors and develop therapeutics to treat vascular reperfusion injury.
Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose
Authors: Thomas Cuisset, Corinne Frere, Jacques Quilici, Raphael Poyet, Bénédicte Gaborit, Laurent Bali, Olivier Brissy, Pierre-Emmanuel Morange, Marie-Christine Alessi, Jean-Louis Bonnet
Journal: Journal of the American College of Cardiology (2009)
Sleep and the Enuresis Alarm Device
Authors: L I Sireling, A H Crisp
Journal: Journal of the Royal Society of Medicine (1983)

The effect on sleep of the wire-mesh element within the ‘buzzer and pad’ enuresis alarm device was studied using healthy adult volunteers in a single or double crossover design. Polygraphic recording revealed a reduction in the number of shifts between sleep stages, and in the time spent in wakefulness, movement and stage 1, on the nights when the mesh was in the bed. This effect may be responsible for preventing some of the enuretic episodes which would otherwise have occurred at such times.
Suing the state for access to cancer medications: The Brazilian experience.
Authors: Gilberto Lopes, Edna Prado, Alberto J. Montero
Journal: Journal of Clinical Oncology (2015)

e17566 Background: The Federal constitution in Brazil guarantees access to health care, but the paucity of available medical resources relative to wealthier countries, disparities in their distribution, and the rising cost of medications often lead patients to take legal recourse to access cancer care. It is estimated that there are approximately 240,000 health-related lawsuits at several levels in the Brazilian judiciary today. Little has been published on access to cancer medications through court orders. Methods: We had access to a de-identified commercial database of 80,462 cancer cases treated in Brazilian public and private healthcare systems between January, 2012 and December, 2014. Descriptive statistics were used to present the data. We extracted information on diagnosis, age, gender, stage, medications and source of payment for care. Results: 2,862 patients (3.56% of the total number of patients with cancer in the database) obtained their medications through the legal system. This number increased by 65.5% over two years—from 426 in the first half of 2012 (3.32% of all patients) to 705 in the second half of 2014 (4.79% of all pts). Of patients treated in the private sector, 1,483 of 38,326 (3.87%) took legal recourse to access medications, as compared to 1,379 of 42,136 (3.27%) in the public system. Drugs most commonly obtained through court orders were: trastuzumab, sunitinib, erlotinib, capecitabine, and abiraterone. The process is very dynamic, however. Court orders for trastuzumab decreased from 109 in the first half of 2012 to 29 in the second half of 2014, likely due to its incorporation into the public health care system. As coverage for regulatory agency-approved oral drugs became mandatory in the private setting in 2014, it is possible that we will see a decrease in the number of court orders for these as well. As an example, the number of patients who had access to sunitinib through the legal system decreased from 153 in 2012 to 104 in 2014. Conclusions: An increasing minority of cancer patients in Brazil take legal action to obtain access to cancer medications. Further studies are clearly warranted to understand the medical, political and economic implications of this phenomenon.
Second solid malignancies after combined modality therapy for Hodgkin's disease.
Authors: R Doria, T Holford, L R Farber, L R Prosnitz, D L Cooper
Journal: Journal of Clinical Oncology (1995)

PURPOSE To determine the actuarial incidence (AI) and relative risk (RR) of second solid malignancies (SSM; solid tumors and non-Hodgkin's lymphoma) in patients with Hodgkin's disease who were treated with chemotherapy and adjuvant, low-dose radiation (combined modality therapy; CMT). PATIENTS AND METHODS From 1969 to 1983, 102 patients with previously untreated advanced Hodgkin's disease (group A) and 81 patients with recurrent disease after radiation (group B) were treated with CMT. Patients were observed for the development of solid tumors (ST) and non-Hodgkin's lymphoma (NHL), and the AI and RR were calculated. RESULTS Nearly half of the patients entering remission were observed for greater than 15 years. At 20 years, the AI for SSM was 12% in group A versus 41% in group B (P = .009). The overall RR for developing a ST in group A was 1.88 (not significant) versus 8.84 in group B (95% confidence interval, 5.3 to 15.4). The difference in the RR between groups A and B was significant (P &lt; .001). The RR for developing NHL was significantly increased in both groups, but the difference between groups was not significant. CONCLUSION Previously untreated patients with advanced disease who were treated with CMT (group A) had a modest but not significant increase in the RR of ST; however, patients treated with CMT for recurrent disease (group B) had a highly significant increase in the RR of ST. Possible explanations for the increase in ST in group B include more cumulative radiation or a greater carcinogenic effect of chemotherapy in previously irradiated patients, but it also is possible that the increase is due to a longer follow-up time.
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Authors: Milena P. Mak, Pan Tong, Lixia Diao, Robert J. Cardnell, Don L. Gibbons, William N. William, Ferdinandos Skoulidis, Edwin R. Parra, Jaime Rodriguez-Canales, Ignacio I. Wistuba, John V. Heymach, John N. Weinstein, Kevin R. Coombes, Jing Wang, Lauren Averett Byers
Journal: Clinical Cancer Research (2015)

We previously demonstrated the association between epithelial-to-mesenchymal transition (EMT) and drug response in lung cancer using an EMT signature derived in cancer cell lines. Given the contribution of tumor microenvironments to EMT, we extended our investigation of EMT to patient tumors from 11 cancer types to develop a pan-cancer EMT signature.Using the pan-cancer EMT signature, we conducted an integrated, global analysis of genomic and proteomic profiles associated with EMT across 1,934 tumors including breast, lung, colon, ovarian, and bladder cancers. Differences in outcome and in vitro drug response corresponding to expression of the pan-cancer EMT signature were also investigated.Compared with the lung cancer EMT signature, the patient-derived, pan-cancer EMT signature encompasses a set of core EMT genes that correlate even more strongly with known EMT markers across diverse tumor types and identifies differences in drug sensitivity and global molecular alterations at the DNA, RNA, and protein levels. Among those changes associated with EMT, pathway analysis revealed a strong correlation between EMT and immune activation. Further supervised analysis demonstrated high expression of immune checkpoints and other druggable immune targets, such as PD1, PD-L1, CTLA4, OX40L, and PD-L2, in tumors with the most mesenchymal EMT scores. Elevated PD-L1 protein expression in mesenchymal tumors was confirmed by IHC in an independent lung cancer cohort.This new signature provides a novel, patient-based, histology-independent tool for the investigation of EMT and offers insights into potential novel therapeutic targets for mesenchymal tumors, independent of cancer type, including immune checkpoints.
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
Authors: E.M. Hersh, M. Del Vecchio, M.P. Brown, R. Kefford, C. Loquai, A. Testori, S. Bhatia, R. Gutzmer, R. Conry, A. Haydon, C. Robert, S. Ernst, J. Homsi, J.J. Grob, K. Kendra, S.S. Agarwala, M. Li, A. Clawson, C. Brachmann, M. Karnoub, I. Elias, M.F. Renschler, A. Hauschild
Journal: Annals of Oncology (2015)
Dual Targeting of JAK2 Signaling with a Type II JAK2 Inhibitor and of mTOR with a TOR Kinase Inhibitor Induces Apoptosis in CRLF2-Rearranged Ph-like Acute Lymphoblastic Leukemia
Authors: Ce Shi, Lina Han, Yoko Tabe, Hong Mu, Shuo-Chieh Wu, Jin Zhou, Zhihong Zeng, David A Fruman, Sarah K Tasian, David M. Weinstock, Marina Konopleva
Journal: Blood (2014)
P1139 : Testosterone suppresses hepatic inflammation by the down-regulation of IL-17, CXCL-9 And CXCL-10 in a mouse model of experimental cholangitis
Authors: D. Schwinge, A. Carambia, A. Quaas, T. Krech, C. Wegscheid, G. Tiegs, I. Prinz, A.W. Lohse, J. Herkel, C. Schramm
Journal: Journal of Hepatology (2015)
Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation
Authors: Binh L. Phong, Lyndsay Avery, Tina L. Sumpter, Jacob V. Gorman, Simon C. Watkins, John D. Colgan, Lawrence P. Kane
Journal: The Journal of Experimental Medicine (2015)

T cell (or transmembrane) immunoglobulin and mucin domain protein 3 (Tim-3) has attracted significant attention as a novel immune checkpoint receptor (ICR) on chronically stimulated, often dysfunctional, T cells. Antibodies to Tim-3 can enhance antiviral and antitumor immune responses. Tim-3 is also constitutively expressed by mast cells, NK cells and specific subsets of macrophages and dendritic cells. There is ample evidence for a positive role for Tim-3 in these latter cell types, which is at odds with the model of Tim-3 as an inhibitory molecule on T cells. At this point, little is known about the molecular mechanisms by which Tim-3 regulates the function of T cells or other cell types. We have focused on defining the effects of Tim-3 ligation on mast cell activation, as these cells constitutively express Tim-3 and are activated through an ITAM-containing receptor for IgE (FcεRI), using signaling pathways analogous to those in T cells. Using a variety of gain- and loss-of-function approaches, we find that Tim-3 acts at a receptor-proximal point to enhance Lyn kinase-dependent signaling pathways that modulate both immediate-phase degranulation and late-phase cytokine production downstream of FcεRI ligation.
COP1 and DET: Conserved regulatory molecules in photomorphogenesis and cancer
Authors: Vishva M. Dixit
Journal: Cancer Research (2005)

SY16-3  COP1 ( constitutively photometric 1) and DET ( De-Etiolated ) function to repress plant photomorphogenesis, the light mediated program of plant development. Mutants of COP1 and DET are constitutively photomorphogenic, and this has been attributed to their inability to negatively regulate the plant transcription factors LAF1 and HY5. The role of COP1 and DET in mammalian cells is less well characterized. We have recently shown that the tumor-suppressor protein p53 is a COP1 interacting protein. COP1 functions as an E3 ubiquitin ligase and increases p53 turnover by targeting it for proteosomal degradation. Depletion of COP1 stabilizes p53 and arrests cells in the G1 phase of the cell cycle. As COP1 is over expressed in many tumors it may represent a mechanism to overcome the tumor suppressive function of p53. In contrast to COP1, human DET promotes ubiquitination and degradation of the proto-oncogenic transcription factor c-Jun by assembling a multisubunit ubiquitin ligase containing DNA Damage Binding Protein-1 (DDB1), cullin 4A ( CUL4A ), Regulator of Cullins-1 ( ROC1), and COP1. The physiological relevance of the COP-DET axis will be discussed.
Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells
Authors: Alan L Chang, Jason Miska, Derek A Wainwright, Mahua Dey, Jian Qiao, Peter Pytel, Yu Han, Lingjiao Zhang, Irina V Balyasnikova, Atique U Ahmed, Maciej S Lesniak
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults with a median survival of 14.6 months despite surgery, radiotherapy, and chemotherapy. One hallmark of GBM is the accumulation of potently immunosuppressive regulatory T cells (Tregs) and
Porphysomes: Multimodal Nanoparticle for Primary Tumor Delineation and Lymphatic Metastasis Mapping in a Head‐and‐Neck Cancer Rabbit Model (Adv. Healthcare Mater. 14/2015)
Authors: Nidal Muhanna, Thomas D. MacDonald, Harley Chan, Cheng S. Jin, Laura Burgess, Liyang Cui, Juan Chen, Jonathan C. Irish, Gang Zheng
Journal: Advanced Healthcare Materials (2015)

On page 2164, J. Chen, J.C. Irish, G. Zheng, and co-workers show how 64 Cu-porphysome nanoparticles enable superior delineation of neoplastic tissues, metastatic lymph nodes, and vascular drainage on a head and neck cancer orthotopic rabbit model by PET imaging. Their selective fluorescence activation in tumor and metastatic lymph nodes permits intraoperative fluorescence guided surgeries.
A weight-management camp followed by weekly after-school lifestyle education sessions as an obesity intervention for Qatari children: a prospective cohort study
Authors: Michael James Taylor, Ivo Vlaev, David Taylor, Paul Gately, Mohamed Ahmedna, Abdelhamid Kerkadi, Jackie Lothian, Aziza Alsaadi, Mohamed Al-Kuwari, Suhaila Gholoum, Hanan Al-Kuwari, Ara Darzi
Journal: The Lancet (2015)
Oncology and hope.
Authors: E Kodish, S G Post
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.7.1817 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7602370 Oncology and hope. E KodishxE KodishSearch for articles by this author , S G PostxS G PostSearch for articles by this author Show More Department of Pediatrics, Rainbow Babies and Childrens Hospital, Cleveland, OH 44106, USA. https://doi.org/10.1200/JCO.1995.13.7.1817 First Page PDF © 1995 by American Society of Clinical Oncology
Macrophages, Inflammation, and Lung Cancer
Authors: Emma M. Conway, Larissa A. Pikor, Sonia H. Y. Kung, Melisa J. Hamilton, Stephen Lam, Wan L. Lam, Kevin L. Bennewith
Journal: American Journal of Respiratory and Critical Care Medicine (2015)

Section:ChooseTop of pageAbstract <<The Spectrum of Macrophag...Macrophages in CancerTAMs and Lung Cancer Prog...Treatment OptionsConclusionsReferencesCITING ARTICLES